With the commencement of GMP manufacturing operations, OrganaBio’s CDMO offers the cell therapy industry ready access to flexible manufacturing solutions and clinical grade cellular raw materials.
OrganaBio, a cell therapy CDMO, expands manufacturing with ISO 7 cleanrooms for 3rd party manufacturing and GMP cellular starting material production.
Axol Bioscience Announces CiPA-Validated Human iPSC-Derived Ventricular Cardiomyocytes
Axol Bioscience’s CiPA-validated ventricular cardiomyocytes can be used as a robust cardiotoxicity measurement tool.
June 7, CAMBRIDGE, England & EDINBURGH, Scotland – Axol Bioscience Ltd., an established provider of iPSC-derived cells, media, and characterization services for life science discovery, today announced that its human induced pluripotent stem cell (iPSC)-derived ventricular cardiomyocytes have undergone comprehensive in vitro pro-arrhythmia assay (CiPA) validation. Using this assay, the cells were shown to be suitable for measuring cardiotoxicity, offering scientists a robust cardiac model for drug discovery and screening. [Read more…]
Defined Bioscience to Develop Stem Cells and iPSC-derived Tissue for Life Science and Cultivated Meat Applications
Defined Bioscience Announces Formation of Its Scientific Advisory Board
San Diego, CA, June 15, 2022 — Defined Bioscience, a life science tools company pioneering the development of next generation ingredients for cell culture, today announced the formation of its scientific advisory board (SAB). The SAB is comprised of a distinguished group of academic and industry experts who will advise the Defined Bioscience team on the development and commercialization of cell culture reagents, growth medium and kits to consistently grow high quality stem cells and iPSC-derived tissue with applications in life science and cultivated meat. [Read more…]
A new automated iPSC high-throughput induction system to induce thousands of iPSC lines simultaneously: To be presented at ISSCR 2022 Annual Meeting
Palo Alto, California, June 14, 2022 – I Peace, Inc. (CEO: Koji Tanabe), a Palo Alto-based GMP cell manufacturing CDMO and personal iPSC banking provider, announced that the company has succeeded in developing a propriety automated iPSC high-throughput induction system to induce thousands of iPSC lines simultaneously. There are various automated cell processing/expansion systems in the market today, but this is the first high-throughput, automated cell processing system that is capable of inducing iPSCs from somatic cells. [Read more…]
